Acurion

What Acurion does

Acurion is a precision oncology technology company founded in 2021 and headquartered in San Diego, California, that develops OncoGaze™, an AI-driven diagnostic platform analyzing routine H&E-stained pathology slides to detect actionable cancer biomarkers within minutes, with an initial focus on Homologous Recombination Deficiency (HRD) for ovarian, breast, and pancreatic cancers. The underlying technology is a proprietary deep learning architecture, protected by five pending patents with over 300 claims, trained on thousands of annotated pathology samples and developed by oncologists and cancer geneticists at UC San Diego; the company claims 1.8-3.1x higher HRD detection sensitivity than standard molecular tests and results delivery measured in minutes versus 3-8 weeks for NGS-based testing. The technology was co-invented by founders including Dr. Ludmil Alexandrov (CSO, pioneer of mutational signatures) and Dr. Scott Lippman (former UCSD Moores Cancer Center Director), with a scientific advisory board including Qualcomm co-founder Irwin Jacobs and Yale Cancer Center Director Eric Winer.

Acurion operates a usage-based diagnostic testing services revenue model, selling biomarker detection as a service to hospital pathology labs and cancer centers under quote-based enterprise contracts, though the platform remains pre-commercial as it advances through clinical validation. The company's go-to-market combines enterprise field sales targeting major hospital systems and academic medical institutions with event-driven awareness (TechCon SoCal 2026, K-Startup Grand Challenge 2025). Current named engagements are predominantly research and validation-oriented rather than revenue-generating: UC San Diego Moores Cancer Center, Korean hospital partnerships (Korea University Medicine, CHA Hospital Center), a strategic partnership with the Pancreatic Cancer Action Network, and a CLIA lab commercialization agreement. Geographic footprint is being expanded with the US as the home market, Korea via K-Startup Grand Challenge and a planned 2026 Korean subsidiary, and Brazil as a stated third core market.

Name

Acurion

Legal name

Acurion

Website

https://acurionhealth.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Acurion is a San Diego-based precision oncology company that developed OncoGaze™, an AI platform extracting cancer biomarker insights from routine pathology slides to enable rapid, tissue-sparing precision treatment decisions for ovarian, breast, and pancreatic cancer patients at hospitals and cancer centers.

Ownership category

akta.pro rank

Product category

AI Precision Oncology Diagnostics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

Keywords

• AI diagnostics platform
• Precision oncology
• Cancer biomarker detection
• Digital pathology
• Genomic biomarkers

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Diagnostic Testing Services: OncoGaze provides biomarker detection as a diagnostic service, analyzing routine pathology slides from healthcare institutions and returning results within minutes. The company is advancing toward clinical deployment and broader adoption in hospital and cancer center settings.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Acurion develops and commercializes OncoGaze™, an AI-driven diagnostic platform that analyzes routine H&E-stained pathology slides using proprietary deep learning to detect actionable cancer biomarkers, most notably Homologous Recombination Deficiency (HRD), for precision oncology decision support. The platform delivers genomic biomarker predictions in minutes from existing tissue samples, targeting hospital pathology labs, academic cancer centers, pharmaceutical trial sponsors, and CLIA laboratory partners.

Product overview

Acurion offers a single unified product platform called OncoGaze™, an AI-driven cancer biomarker detection system. The platform analyzes standard H&E-stained pathology slides to extract genomic insights and detect actionable biomarkers such as HRD (Homologous Recombination Deficiency). OncoGaze™ serves as both the core diagnostic tool and the proprietary technology brand for the company, providing instantaneous, scalable, and accessible precision medicine for ovarian, breast, and pancreatic cancers.

Differentiator

Problem solved

Functional benefit

Brands

• OncoGaze™: AI-driven diagnostic platform that extracts cancer biomarkers from routine pathology slides for precision oncology applications, including HRD detection for ovarian, breast, and pancreatic cancers.

Products and services

• OncoGaze™ AI-powered diagnostic platform that analyzes routine H&E-stained pathology slides using deep learning to detect cancer biomarkers, particularly Homologous Recombination Deficiency (HRD), enabling precision oncology treatment decisions within minutes for hospital systems, cancer centers, and pathology labs treating ovarian, breast, and pancreatic cancer patients.

Quantifiable outcome

• 1.8-3.1x more HRD detection than standard molecular tests - identifies more HRD-positive patients than NGS testing
• +3 more outcomes

Named customers8 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• Pancreatic Cancer Action NetworkcoreStrategic or Co-development Partner · 2 July 2025Partnership to accelerate pancreatic cancer diagnostics using AI and real-world patient data. Announced July 2025.
• Korea University MedicinecoreStrategic or Co-development Partner · 1 January 2025Korean hospital partnership through K-Startup Grand Challenge 2025 for OncoGaze validation and clinical deployment in Korean market.
• CHA Hospital CentercoreStrategic or Co-development Partner · 1 January 2025Korean hospital partnership through K-Startup Grand Challenge 2025 for OncoGaze validation and clinical deployment in Korean market.
• CLIA LaboratorycoreStrategic or Co-development PartnerCollaboration and commercialization agreement with leading oncology CLIA lab for test development and clinical deployment.

Recent moves7 records

Expansion highlights6 records

Direct peers

• Natera: Natera provides comprehensive genomic profiling in oncology including HRD testing via molecular methods, with established commercial scale and hospital sales infrastructure. Acurion's VP of Product previously led growth strategy at Natera, indicating direct competitive overlap in HRD/precision oncology testing.
• Myriad Genetics: Myriad Genetics is the pioneer in BRCA/HRD testing (BRACAnalysis, myChoice HRD) with established FDA-cleared assays, payer reimbursement, and clinical guideline inclusion. Direct competitor in HRD biomarker testing for ovarian, breast, and pancreatic cancer treatment selection.
• Paige.AI: Paige applies AI/deep learning to pathology images for cancer detection and biomarker prediction, with FDA-cleared products for prostate and breast cancer. Competes with Acurion in AI-driven image-based cancer biomarker detection for hospital pathology workflows.
• SOPHiA GENETICS: SOPHiA GENETICS offers an AI-powered HRD detection solution for homologous recombination deficiency analysis using deep learning on sequencing data. Acurion's VP of Product Development previously led the launch of SOPHiA's HRD Solution, making this a direct competitor with overlapping technology and target customer base.
• PathAI: PathAI develops AI-powered pathology solutions for cancer diagnostics and biomarker detection, partnering with pharmaceutical companies and health systems. Direct competitor in applying deep learning to H&E pathology slides for oncology biomarker discovery.
• Ibex Medical Analytics: Ibex develops AI-powered cancer diagnostics from H&E pathology slides, with clinically-proven products deployed in pathology labs worldwide. Direct competitor using similar deep learning approach to extract clinical insights from standard pathology images.

Emerging players

• Owkin: Owkin applies AI/federated learning to pathology and clinical data for precision oncology research and biomarker discovery. Emerging player with overlapping AI-pathology and oncology biomarker focus, primarily partnering with pharma for drug development.
• Nucleai: Nucleai applies AI to pathology images for biomarker prediction and treatment response, with focus on spatial biology. Emerging competitor in AI pathology with overlapping technology approach and similar hospital/biopharma customer base.

Broad incumbents

• Tempus: Tempus combines molecular sequencing with AI-driven analytics for precision oncology, offering comprehensive genomic profiling and biomarker testing at scale. A broader incumbent with overlapping goals in AI-enabled precision oncology decision support for oncologists.
• Foundation Medicine (Roche): Foundation Medicine provides comprehensive genomic profiling (FoundationOne CDx) widely used in oncology treatment selection, including HRD-related biomarkers. A large established incumbent with FDA-approved comprehensive genomic test that competes in the same clinical use cases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/io9_ai
• LinkedInlinkedin.com/company/acurionhealth

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acurion